Laura Nuño

Dr. Laura Nuño


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
LNLaura Nuño
Laura Nuño
MNMarta Novella-Navarro
Marta Novella-Navarro
GBGema Bonilla
Gema Bonilla
KFKaren Franco-Gómez
Karen Franco-Gómez
PAPilar Aguado
Pilar Aguado
ABAlejandro Balsa
Alejandro Balsa
Table 1 Patients with COVID-19 characteristics Demographics Female sex, n (%) 80 (65.6) Caucasian ethnicity, n (%) 98 (80.3) Age (mean±SD), 58.3±16.3 Comorbidity, n (%) Hypertension 48 (39.3) Obesity 27 (23.6) Chronic pulmonary disease 20 (16.4) Cardiovascular disease 21 (17.2) Diabetes mellitus 14 (11.5) Active smokers 7 (5.6) Treatment with ACE/ARB, n (%) 34 (27.9) Rheumatic diseases, n (%) RA 41 (33.6) SpA 24 (19.7) SLE 13 (10.7) PsA 13 (10.7) Miscellaneous* 31 (25.4) Duration of rheumatic disease (mean±SD), years 12.2±9.3 Concomitant treatment, n (%) Hydroxychloroquine 26 (21.3) Glucocorticoids 48 (39.3) cDMARDs 80 (65.6) Methotrexate 54 (44.3) Sulfasalazine 19 (15.6) Leflunomide 13 (10.7) Azathioprine 2 (1.6) Cyclophosphamide 1 (0.8) bDMARDs/tsDMARDs 42 (34.4) Anti-TNF 28 (23.0) Rituximab 7 (5.7) Abatacept 3 (2.5) Tocilizumab 1 (0.8) Sarilumab †-Secukinumab 0 (0.0) Tofacitinib 1 (0.8) Baricitinib 1 (0.8) Symptoms, n (%) Dry, non-productive cough 84 (74.3) Fever 74 (64.3) Dyspnoea 59 (50.0) Arthromyalgia 42 (36.5) Anosmia/ageusia 41 (37.5) Nausea/vomiting 39 (33.9) Respiratory insufficiency, n (%) 54 (52.5) Non-invasive oxygen supplementation, n (%) 50 (41.0) Pneumonia, n (%) 67 (54.9) Time from disease onset to hospital admission, days (median, IQR) 7.2 (4.1-10.5) Hospital admission, n (%) 69 (56.6) ICU admission, n (%) 6 (4.9) Time of hospital admission, days (median, IQR) 8.0 (5.0-15.2) COVID-19 specific treatment, n (%) Hydroxychloroquine 76 (62.3) Azithromycin 50 (41.0) Glucocorticoids 8 (6.6) Lopinavir/ritonavir 6 (4.9) Anti-IL6 6 (4.9) Anti-IL1 2 (1.6) IVIg 3 (2.5)

2 September 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LNLaura Nuño
Laura Nuño
BJBeatriz Esther Joven
Beatriz Esther Joven
PCPatricia Esmeralda Carreira
Patricia Esmeralda Carreira
VMValentina Maldonado-Romero
Valentina Maldonado-Romero
CLCarmen Larena-Grijalba
Carmen Larena-Grijalba
FLFrancisco Javier López-Longo
Francisco Javier López-Longo

10 April 2019 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LNLaura Nuño
Laura Nuño
BJBeatriz Esther Joven
Beatriz Esther Joven
PCPatricia E. Carreira
Patricia E. Carreira
VMValentina Maldonado‐Romero
Valentina Maldonado‐Romero
CLCarmen Larena‐Grijalba
Carmen Larena‐Grijalba
FLFrancisco Javier López‐Longo
Francisco Javier López‐Longo

31 December 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
CRCristina Regueiro
Cristina Regueiro
DCDesire Casares‐Marfil
Desire Casares‐Marfil
KLKarin Lundberg
Karin Lundberg
RKRachel Knevel
Rachel Knevel
MAMarialbert Acosta‐Herrera
Marialbert Acosta‐Herrera
AGAntonio Gonzalez
Antonio Gonzalez


23 September 2024 in Rheumatology International
Verified
Journal Article
Open access
PDF file
JAJordi Anton
Jordi Anton
JMJuan Manuel Mosquera
Juan Manuel Mosquera
JCJoan Calzada
Joan Calzada
EIEstíbaliz Iglesias
Estíbaliz Iglesias
AZAndrea Zacarías
Andrea Zacarías
LCLoreto Carmona
Loreto Carmona
To describe the characteristics of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD), compare their presentation and evolution, and analyse possible complication predictors. Multicenter study. Data were retrieved from a hospital-based study of patients with a diagnosis or suspected diagnosis of sJIA or AOSD according to the responsible physician and followed-up for at least one year. Descriptive variables (classification criteria, clinical manifestations, complications, family, and personal history) were collected at disease onset and during follow-up. We present the clinical characteristics of 326 patients, 67% of whom had a diagnosis of sJIA and 33% of AOSD. Clinical manifestation frequencies were similar between the two groups, except for odynophagia, which was significantly more frequent in AOSD than in sJIA (78.4% vs. 25.5%; p < 0.0001). Among the complications, macrophage activation syndrome (MAS) was significantly more common in sJIA than in AOSD (24.4% vs. 9.5%; p = 0.002), to the extent that an sJIA diagnosis significantly increased the risk of MAS, together with serositis presence, and the need for biological therapy. Patients with sJIA and AOSD showed similar characteristics, supporting the idea that they are both part of Still’s disease, but are expressed at different ages. Differences in manifestations and complications might be due to different management between diseases and immune response maturity.